22,49 $
2,22 % gestern
Nasdaq, 8. Oktober, 22:10 Uhr
ISIN
US8902604094
Symbol
TNXP
Berichte

Tonix Pharmaceuticals Holding Corp. Aktie News

Positiv
Proactive Investors
8 Tage alt
Tonix Pharmaceuticals (NASDAQ:TNXP) announced the appointment of Ganesh Kamath as its head of market access, effective September 29, 2025.   The biotechnology company said Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix.
Neutral
GlobeNewsWire
9 Tage alt
Mr. Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix On August 15, 2025, the U.S. Food and Drug Administration approved Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, the first new fibromyalgia therapy in more than 15 years US Launch of Tonmya expected in the fourth quarter of 2025 CHATHAM, N...
Neutral
GlobeNewsWire
10 Tage alt
Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND
Neutral
GlobeNewsWire
21 Tage alt
Tonix anticipates filing the IND application in the fourth quarter of 2025 TNX-102 SL is a potential first-in-class treatment for targeting the disturbed sleep associated with depression TNX-102 SL is FDA-approved for the treatment of fibromyalgia CHATHAM, N.J., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company with m...
Neutral
GlobeNewsWire
22 Tage alt
Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1)
Neutral
GlobeNewsWire
etwa ein Monat alt
Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA approved treatment for fibromyalgia in over 15 years Two pivotal Phase 3 studies demonstrated Tonmya significantly reduced fibromyalgia pain compared to placebo Tonmya showed consistent improvements across core fibromyalgia symptoms, including widespread pain, sleep disturbance and fatigue T...
Neutral
GlobeNewsWire
etwa ein Monat alt
CHATHAM, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D.
Positiv
Seeking Alpha
etwa 2 Monate alt
The Tonix Pharmaceuticals Holding Corp. stock price has pulled back so much, and they hold a clear campaign runway for Tonmya into 2026. Despite approval, TNXP shares dropped due to concerns over valuation, potential dilution, and uncertainty around commercialization and pricing. Tonmya's novel formulation and high unmet need could drive strong adoption, with revenue potential of $219M–$365M an...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen